Human papilloma virus vaccines: Current scenario

Area of Science:

• Virology
• Immunology
• Public Health

Background:

• Genital human papillomavirus (HPV) infection is the most common sexually transmitted infection globally, with significant morbidity and mortality.
• HPV infection is a major cause of cervical, anal, vulvar, vaginal, penile, and oropharyngeal cancers.

Purpose of the Study:

• To review the epidemiology and clinical implications of HPV infection.
• To discuss the role and efficacy of currently available prophylactic HPV vaccines.
• To highlight the need for India-specific data and continued global surveillance.

Main Methods:

• Literature review of HPV epidemiology, clinical manifestations, and vaccine efficacy.
• Analysis of data on commercially available HPV vaccines (Gardasil and Cervarix).
• Discussion of vaccination strategies and public health impact.

Main Results:

• Two prophylactic HPV vaccines (quadrivalent and bivalent) are available, targeting specific HPV types.
• Vaccines are safe and highly effective in preventing HPV-induced anogenital warts, precancerous lesions, and cervical cancer.
• Vaccine efficacy is maximized when administered before sexual debut, providing long-term protection.

Conclusions:

• Effective HPV vaccination programs, particularly in young females, can significantly reduce HPV-related cancer incidence and mortality.
• Further research is needed on India-specific HPV epidemiology and vaccine efficacy.
• Continued global surveillance and development of novel vaccines are essential.